New Medicine Service costeffective in England

New Medicine Service costeffective in England PharmacoEconomics & Outcomes News 784, p25 - 12 Aug 2017 New Medicine Service cost effective in England The English community pharmacy New Medicine Service (NMS) for patients initiating new treatment for a chronic condition appears to be cost effective, according to findings of a study published in PharmacoEconomics. Markov models for diseases targeted by the NMS (hypertension, type 2 diabetes mellitus, chronic obstructive pulmonary disease, asthma and antiplatelet regimens) were used to evaluate the impact of the NMS on patient adherence and the cost effectiveness of the NMS compared with normal practice, from the perspective of NHS England over a lifetime time horizon. The models were populated with data from a 10-week randomised controlled trial in a trial in 504 patients. Overall, the NMS was estimated to gain a mean of 0.04 additional QALYs per patient compared with ** – ), and normal practice, at a reduced cost ( £139 therefore dominated (more effective and less costly) normal practice. Estimated incremental cost- effectiveness ratios ranged from –£44 614 per QALY gained for beclometasone to £1845 per QALY gained for tiotropium bromide. The NMS had a 96.7% probability of being cost effective compared with normal practice at a willingness-to-pay threshold of £20 000 per QALY gained. "Our study suggests that the NMS increased patient medicine adherence compared with normal practice, which translated into increased health gain at reduced overall cost," concluded the authors. "From inception of the NMS to the end of August 2016, 3.59 million consultations have been claimed for with over 820,000 in the year 2015/16. From the results of this economic evaluation, this suggests £75.4 million short-term savings to the NHS, £517.6 million long-term cost savings to the NHS and 179,500 QALYs gained," they said. * National Health Service ** 2014 British pounds Elliott RA, et al. Cost Effectiveness of Support for People Starting a New Medication for a Long-Term Condition Through Community Pharmacies: An Economic Evaluation of the New Medicine Service (NMS) Compared with Normal Practice. PharmacoEconomics : 3 Aug 2017. Available from: URL: http:// 1173-5503/17/0784-0001/$14.95 Adis © 2017 Springer International Publishing AG. All rights reserved PharmacoEconomics & Outcomes News 12 Aug 2017 No. 784 PharmacoEconomics & Outcomes News Springer Journals

New Medicine Service costeffective in England

1 page

Loading next page...
1 Page
Springer International Publishing
Copyright © 2017 by Springer International Publishing AG
Medicine & Public Health; Pharmacoeconomics and Health Outcomes; Quality of Life Research; Health Economics; Public Health
Publisher site
See Article on Publisher Site

There are no references for this article.

You’re reading a free preview. Subscribe to read the entire article.

DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 12 million articles from more than
10,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Unlimited reading

Read as many articles as you need. Full articles with original layout, charts and figures. Read online, from anywhere.

Stay up to date

Keep up with your field with Personalized Recommendations and Follow Journals to get automatic updates.

Organize your research

It’s easy to organize your research with our built-in tools.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

Monthly Plan

  • Read unlimited articles
  • Personalized recommendations
  • No expiration
  • Print 20 pages per month
  • 20% off on PDF purchases
  • Organize your research
  • Get updates on your journals and topic searches


Start Free Trial

14-day Free Trial

Best Deal — 39% off

Annual Plan

  • All the features of the Professional Plan, but for 39% off!
  • Billed annually
  • No expiration
  • For the normal price of 10 articles elsewhere, you get one full year of unlimited access to articles.



billed annually
Start Free Trial

14-day Free Trial